Table 1. Clinical characteristics of the HGSOC cohort examined in this study.
| Variables | Total Cohort | ||
|---|---|---|---|
| N = 93 (%) | Median OS (months) | p-value (Log-rank) | |
| Age (years) | |||
| Mean | 60.9 | ||
| Median | 60.0 | ||
| Range | 40.0–86.0 | ||
| Outcome | |||
| Follow-up (months) | 4.0–183.0 | ||
| Median follow-up (months) | 87.0 | ||
| Death from ovarian cancer | 64 (68.8) | ||
| Death from other | 1 (1.1) | ||
| Death from unknown | 4 (4.3) | ||
| Alive | 24 (25.8) | ||
| Stage (N = 92) | |||
| I | 5 (5.4) | N/A | |
| II | 4 (4.3) | 81.0 | |
| III | 69 (75.0) | 38.0 | |
| IV | 14 (15.2) | 15.0 | 0.0060a |
| Grade | |||
| 2 | 30 (32.3) | 44.0 | |
| 3 | 63 (67.7) | 32.0 | 0.1443 |
| Residual disease (N = 60) | |||
| 0 | 19 (31.7) | 92.0 | |
| > 0 to 1 | 24 (40.0) | 38.0 | |
| > 1 to 2 | 5 (8.3) | 21.0 | |
| > 2 | 12 (20.0) | 15.0 | < 0.0001 |
| Complete response | |||
| Yes | 44 (47.3) | 44.0 | |
| No | 49 (52.7) | 28.0 | 0.0459 |
| Menopause (N = 92) | |||
| Pre-menopause | 8 (8.7) | 38.0 | |
| Peri-menopause | 5 (5.4) | 32.0 | |
| Post-menoapuse | 79 (85.9) | 35.0 | 0.9590 |
| CTGF expression (%) (N = 88) | |||
| ≤ 90 | 84 (95.5) | 38.0 | |
| > 90 | 4 (4.5) | 9.0 | 0.0006 |
HGSOC = high-grade serous ovarian cancer; OS = overall survival; N/A = not applicable, as median survival has not been reached; CTGF = connective tissue growth factor.
a
Any CTGF expression versus no expression